Aridis Pharmaceuticals is a private biotechnology company focusing on improved alternatives to traditional antibiotics for the treatment of pneumonia and Cystic Fibrosis in addition to a few other conditions.
Athersys (ATHX) is a clinical stage based biopharmaceutical company with an exponentially growing pipeline and an array of products in therapeutics to treat significant and life-threatening diseases.
A company to keep a look out for in the upcoming future is BioDelivery Sciences International (BDSI), a specialty pharmaceutical company with a platform of drug delivery technologies to develop, commercialize, and improve already proven applications of therapeutics.
Pluristem Therapeutics (PSTI) is a developer of placenta-based cell therapies. They have just formed a strategic alliance with Cha Bio&Diostech.
Novavax, Inc (NVAX) is a clinical-stage biopharmaceutical company that strives to create novel vaccines to treat a broad spectrum of diseases around the world.
Cytokinetics (CYTK) is a clinical stage biotechnology company that focuses on the discovery and development of novel molecular therapeutics in relation to muscle function.
Cognoptix and its technology have the ability to overhaul commonly accepted Alzheimer’s Disease diagnostic practices, providing a tool to diagnose the disease at an early stage, thereby increasing the efficacy of current therapies.
Orexo is an emerging specialty pharmaceutical company in route to enter the market with their new medication Zubsolv; an oral medication that dissolves under the tongue to treat opioid addiction.
GreeneStone Healthcare Corp. (OTCBB: GRST) operates medical clinics in Ontario, Canada. GreeneStone adds capacity to an increasingly stretched provincial healthcare system, and provides private alternatives to publicly under-serviced niches. Greenestone President and CEO Shawn Leon spoke with OneMedRadio about market opportunity for clinics in the unique Canadian healthcare system, and evolving valuation drivers in this space.
Metabiomics is developing a noninvasive screening test for colon polyps in colorectal cancer based on human microbiome markers. In an interview with OneMedRadio, Gregory Kuehn, Vice President of Business Development at Metabiomics, explained that the preliminary data showed “sensitivity in excess of 97%” and specificity “as high as 93%.” Metabiomics will present at the upcoming OneMedForumNY 2013 on June 27th.
Copyright © 2024 | WordPress Theme by MH Themes